Last reviewed · How we verify
NCT00877838
A Phase 2a Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura
Phase 2 trial testing NXN-188 in Migraine With Aura in 40 participants. Status unknown.
1 March 2010
Quick facts
| Lead sponsor | Danish Headache Center |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 May 2009 |
| Primary completion | 1 March 2010 |
| Estimated completion | 1 December 2010 |
| Sites | 1 location across Denmark |
Drugs / interventions tested
- NXN-188 — full drug profile →
- Placebo
Conditions studied
- Migraine With Aura — all drugs for Migraine With Aura →
Sponsor
Danish Headache Center — full company profile →
Who can join
Adults 18 to 65, any sex, with Migraine With Aura. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
The severity of headache measured with a 4 point scale (The Headache Severity Score (HSS))
Time frame: 2 hours after dosing -
Absence of headache
Time frame: 2 hours after dosing
Sponsor's own description
The following study is being conducted to explore the safety and effectiveness of a new chemical entity called NXN-188 in subjects with a history of migraine with aura. In this study subjects will treat two attacks of migraine with aura during the aura phase - once with placebo and once with NXN-188.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00877838
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Migraine With Aura
Currently open trials in the same condition.
- NCT07021859 — Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide · NA · recruiting
- NCT05889624 — Responding With Evidence and Access for Childhood Headaches · NA · recruiting
- NCT05903027 — Gepant treAtments: EffectIveNess and tolERability (GAINER) · recruiting
- NCT05484349 — TIzanidine for the Preventive Treatment of Episodic MigrainE （TIME） · Phase 3 · recruiting
- NCT04715685 — Mind Body Balance for Pediatric Migraine · NA · recruiting
Other Danish Headache Center trials
Trials by the same sponsor.
- NCT07451769 — Selective Activation of the Adrenomedullin Receptors in Migraine · NA · not yet recruiting
- NCT07342296 — Induction of Migraine Attacks With Aura Using Pituitary Adenylate Cyclase Activating Polypeptide-38 · NA · not yet recruiting
- NCT07059546 — Hypersensitivity to Adrenomedullin in Post-Traumatic Headache · NA · recruiting
- NCT07021859 — Induction of Migraine Attacks With Aura Using Calcitonin Gene-Related Peptide · NA · recruiting
- NCT06959004 — Substance P-Induced Migraine Attacks Without Aura · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00877838 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Danish Headache Center
- Last refreshed: 27 July 2009
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00877838.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing